ROCOLIP Tablets contains Rosuvastatin. Rosuvastatin produces a greater LDL-cholesterol reduction and attainment of target goals. Rosuvastatin possesses the highest bonding interactions with HMG-CoA reductase, resulting in the most potent inhibition of cholesterol synthesis.

Rosuvastatin has potentially desirable pharmacologic and pharmacokinetic properties, making it a beneficial selection for cholesterol treatment in terms of hepatic selectivity, hydrophilicity, half-life, and biliary excretion. These properties potentially lead to increased efficacy as well as decreased adverse effects and drug interactions with rosuvastatin.

ROCOLIP Tablets contains Rosuvastatin that is a Hydroxymethylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitor.

ROCOLIP Tablets can be used in the treatment of the following conditions:

  • Hyperlipidemia and mixed dyslipidemia
  • Hypertriglyceridemia
  • Hypercholesterolemia
  • Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia)
  • Slowing the progression of Atherosclerosis
  • Primary prevention of cardiovascular diseases

One ROCOLIP Tablet daily with/without food at any time of the day or as directed by Physician.

Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor for cholesterol. The primary site of action of rosuvastatin is the liver, the target organ for cholesterol lowering. Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.